Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
LEHI, Utah — March 2, 2026—Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver acompany presentation at the BIO Investment & Growth Summit.
David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy, platform, and clinical programs.
Presentation Details
Event: BIO Investment & Growth Summit
Date/Time: Monday, March 2, 2026, at 2:30 PM
Location: Ballroom I, Salon C
About NEK7
NEK7 is a critical regulator of inflammasome activation and a required component for the assembly and activation of the NLRP3 inflammasome. Activation of this pathway can drive the release of proinflammatory cytokines, including IL-1β and IL-18, contributing to chronic inflammation across hematology, cardiometabolic, pain, and other inflammation-driven diseases. Targeting NEK7 offers a pathway-level approach to modulating NLRP3 inflammasome activity upstream, providing a differentiated strategy versus blocking individual downstream cytokines.
About Halia Therapeutics
Halia Therapeutics is a biotechnology company developing first-in-class inflammasome inhibitors. We target the root causes of inflammation-driven diseases to create transformative therapies.
Media Contact
Taylor Avei
Director of Business Development
Halia Therapeutics
info@haliatx.com
LEHI, Utah — March 2, 2026—Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver acompany presentation at the BIO Investment & Growth Summit.
David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy, platform, and clinical programs.
Presentation Details
Event: BIO Investment & Growth Summit
Date/Time: Monday, March 2, 2026, at 2:30 PM
Location: Ballroom I, Salon C
About NEK7
NEK7 is a critical regulator of inflammasome activation and a required component for the assembly and activation of the NLRP3 inflammasome. Activation of this pathway can drive the release of proinflammatory cytokines, including IL-1β and IL-18, contributing to chronic inflammation across hematology, cardiometabolic, pain, and other inflammation-driven diseases. Targeting NEK7 offers a pathway-level approach to modulating NLRP3 inflammasome activity upstream, providing a differentiated strategy versus blocking individual downstream cytokines.
About Halia Therapeutics
Halia Therapeutics is a biotechnology company developing first-in-class inflammasome inhibitors. We target the root causes of inflammation-driven diseases to create transformative therapies.
Media Contact
Taylor Avei
Director of Business Development
Halia Therapeutics
info@haliatx.com
حول هاليا ثيرابيوتك
Halia Therapeutics هي شركة أدوية بيولوجية في المرحلة السريرية تركز على علاج الأسباب الجذرية للالتهاب. من خلال الاستفادة من الرؤى الجينية والاكتشافات المدعومة بالذكاء الاصطناعي، تقوم Halia ببناء خط أنابيب قوي من العلاجات الجديدة القائمة على المرونة الجينية التي تستهدف المسارات الالتهابية في الأمراض التي تتراوح من الاضطرابات الأيضية إلى التنكّس العصبي والأورام الدموية الخبيثة.
تتمثل مهمة Halia في إنشاء علاجات تعتمد على البيانات لا تطيل العمر فحسب، بل تعمل أيضًا على تحسين جودتها. يقع المقر الرئيسي للشركة في ليهي بولاية يوتا، وتعمل بنشاط على تعزيز الشراكات العالمية في الأبحاث السريرية واكتشاف الأدوية والطب الشخصي.
لمعرفة المزيد، تفضل بزيارة www.haliatx.com أو تابعنا على لينكد إن وتويتر @HaliaTx.